Palvella Therapeutics is committed to developing safe and effective therapies that specifically target the root cause of genetic skin diseases.
Location: United States, Pennsylvania, Radnor Township
Total raised: $92.7M
Investors 3
Funding Rounds 3
| Date | Series | Amount | Investors |
| 09.01.2023 | Series D | $37.7M | - |
| 30.05.2020 | Series C | $45M | - |
| 19.12.2018 | - | $10M | - |
Mentions in press and media 14
| Date | Title | Description |
| 03.10.2024 | Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial i... | FDA Orphan Products Grants are based on scientific and technical merit as determined by rare disease and regulatory experts Ongoing Phase 3 trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of micro... |
| 30.01.2023 | Money Moves: Palvella Therapeutics’ Series D, Startup Bucks’ investments and more Philly raises | Money Moves is a column where we chart the funding raises of tech companies across the region. Have a tip? Email us at philly@technical.ly. Palvella Therapeutics’ Series D Palvella Therapeutics, a Berwyn-based late clinical stage biopharma ... |
| 09.01.2023 | Palvella Therapeutics Raises Up To $37.7M Series D Financing | Palvella Therapeutics, a Wayne, PA-basedclinical-stage biopharmaceutical company, raised up to $37.7M in Series D funding. The round was led by Petrichor and Gore Range Capital with participation from Samsara BioCapital, BVF Partners L.P., ... |
| 05.01.2023 | Palvella Therapeutics Announces Series D Financing of Up to $37.7 Million to Accelerate Late-Stage Development and Support Commercialization of Novel Therapies for Serious, Rare Genetic Skin Diseases | Led by new investor Petrichor, with participation from new and existing investors Lead product candidate, QTORIN™ rapamycin, in late-stage clinical development for serious, rare genetic skin diseases with no FDA-approved therapies Top-line ... |
| 05.01.2023 | Palvella Therapeutics Announces Series D Financing of Up to $37.7 Million to Accelerate Late-Stage Development and Support Commercialization of Novel Therapies for Serious, Rare Genetic Skin Diseases | /EIN News/ -- Led by new investor Petrichor, with participation from new and existing investors Lead product candidate, QTORIN™ rapamycin, in late-stage clinical development for serious, rare genetic skin diseases with no FDA-approved thera... |
| 05.01.2023 | Palvella Therapeutics Announces Series D Financing of Up to $37.7 Million to Accelerate Late-Stage Development and Support Commercialization of Novel Therapies for Serious, Rare Genetic Skin Diseases | - |
| 02.07.2020 | Money Moves: These 8 Philly-area companies raised more than $118M total this spring | Money Moves is a column where we chart the funding raises of tech companies across the region. Have a tip? Email us at philly@technical.ly. A handful of Philly-area companies across industries like biosciences and and information sciences h... |
| 30.05.2020 | Palvella Therapeutics Completes $45M Series C | WAYNE, PA, Palvella Therapeutics announced the closing of an oversubscribed $45 million Series C financing. >> Click here for more funding data on Palvella Therapeutics >> To export Palvella Therapeutics funding data to PDF ... |
| 29.05.2020 | Palvella Therapeutics Closes $45M Series C Financing Round | Palvella Therapeutics, Inc., a Wayne, PA – based rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for serious genetic diseases with no approved treatments, raised $45m in S... |
| 28.05.2020 | Palvella Therapeutics Completes $45M Series C Financing | WAYNE, Pa., May 28, 2020 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for serious genetic diseases with no approved t... |
Show more